Repros Therapeutics Inc. (RPRX) announced after the close Wednesday that the FDA has accepted its New Drug Application for the enclomiphene citrate product candidate, formerly known as Androxal.
Repros Therapeutics has gapped open sharply higher Thursday morning and is now up 1.24 at $9.73 on above average volume. The stock has jumped to nearly a 1-month high.
For comments and feedback contact: editorial@rttnews.com
Business News